ALB's Materials Website:
Home > Products > Antibody Drug Conjugates > ADCs Cytotoxin > Monomethyl Auristatin F (MMAF) | CAS Number: 745017-94-1 | Tubulin-Binders

Monomethyl Auristatin F (MMAF) | CAS Number: 745017-94-1 | Tubulin-Binders

  • Inquiry Button

  • Item No.: ADCs-T0006
  • Product Name: Monomethyl Auristatin F (MMAF)
  • CAS Number: 745017-94-1
  • Molecular Formula: C39H65N5O8
  • Molecular Weight: 731.96
  • Purity: 95%
  • Price ($, USD): $388/20mg, $669/50mg, $925/100mg, $1280/200mg, $2199/500mg, $3000/1G ($, USD) Inquiry
  • Synonyms: MMAF; MonoMethylauristatin F; MonoMethyl Auristatin F | MMAF
  • Supplier: ALB Technology Limited
  • COA: COA of Monomethyl Auristatin F (MMAF) | CAS Number: 745017-94-1 | Tubulin-Binders
  • MSDS: MSDS of Monomethyl Auristatin F (MMAF) | CAS Number: 745017-94-1 | Tubulin-Binders

Download SDF file: MMAF_Monomethyl-Auristatin-F_cas-745017-94-1.sdf



Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF) are both tubulin polymerization inhibiter.They are synthetic derivatives of dolastatin 10 and functions as a potent antimitotic agent by inhibiting tubulin polymerization. Monomethyl auristatin E, have been conjugated to antibodies via cleavable linkers (MC-vc-PAB) through internal cysteines.It should be noted that MMAE and MMAF are fully synthetic drugs, which may confer them a price advantage compared to other ADC payloads.

The major difference between MMAE and MMAF is that MMAF possesses a phenylalanine at the C-terminus, contributing to membrane impermeability. It was possible to derivatize MMAF at the amine terminus with a noncleavable linker without any loss of activity, which was not the case for the MMAE analog. The ADC SGN-35 (brentuximab vedotin) composed of MMAE which is bound to a chimeric anti-CD30 monoclonal antibody through a cleavable valine–citruline linker had good clinical results in multiple phase I, II, and III clinical trials. On 19 August 2011, the US Food and Drug Administration (FDA) granted accelerated approval for the use of brentuximab vedotin in relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma under the brand name Adcetris. Currently, brentuximab vedotin is the only FDA-approved ADC and the first approved drug for treating Hodgkin lymphoma in 30 years. The other promising auristatin derivative MMAF entered as a MMAF-ADC by now at least three phase I clinical trials: in subjects with renal cell carcinoma (RCC) of clear cell or papillary histology (AGS-16C3F, AGS-16M8F) and in subjects with CD70-positive non-Hodgkin lymphoma or RCC (SGN-75).


MMAF related articles:


A Quick Inquiry

A Quick Inquiry

Contact Us